ClinicalTrials.gg
CompletedNCT02533401Updated May 2, 2016Results posted

A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

A Phase 2 interventional study of Cyclophosphamide and Fludarabine in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 11 under way, none of them phase 3. Cyclophosphamide · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
95th of 145
34 · median 49
Started
2006
with 6 others
Phase 2
100 of 155
1 open now
Registered
133rd of 155
by date
Lead sponsor
7 of 155
Hoffmann-La Roche

Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 95th largest by enrollment of the 145 interventional ones that give a count, is one of 7 that started in 2006, is one of 100 in phase 2, and was the 133rd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

3 of the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of rituximab in combination with chemotherapy (fludarabine and cyclophosphamide) in participants with B-cell CLL.

03

Conditions studied

  • Lymphocytic Leukemia, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants greater than or equal to (≥) 18 years of age
  • B-cell CLL
  • No previous treatment for leukemia

Exclusion criteria

Exclusion Criteria:

  • History of other within 2 years before study entry, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, prostate cancer, or breast cancer
  • Comorbid condition requiring long-term (greater than [>] 1 month) systemic during study treatment
  • Known infection with or C virus or with (HIV)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Rituximab + Fludarabine + Cyclophosphamide

    Participants will receive rituximab (375 milligrams per meter-squared \[mg/m\^2\] intravenously \[IV\]) on Cycle 1 Day 1, followed by fludarabine (25 mg/m\^2 once daily IV) and cyclophosphamide (250 mg/m\^2 once daily IV) for Days 2 to 4 of Cycle 1. Then rituximab (500 mg/m\^2 IV) will be administered on Day 1 of Cycles 2 to 6, followed by IV fludarabine (25 mg/m\^2 once daily IV) and cyclophosphamide (250 mg/m\^2 once daily IV) on Days 1 to 3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length, and the overall duration of treatment will be approximately 6 months.

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Rituximab

Interventions

  • Cyclophosphamide will be administered IV at 250 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.

  • Fludarabine will be administered IV at 25 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.

  • Rituximab will be administered IV at 375 mg/m\^2 on Day 1 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.

    Also known as: MabThera/Rituxan

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Death or Disease Progression

    Treatment response was monitored throughout the study and assessed using standardized criteria. Disease progression was defined as the occurrence of at least one of the following: greater than or equal to (≥) 50 percent (%) increase in the longest diameter of at least two enlarged lymph nodes, increase in spleen and/or liver size by at least 2 centimeters (cm) from Baseline as determined by measurement below the costal margin, or ≥50% increase in the number of circulating lymphocytes. The percentage of participants with death or documented disease progression at any time during the study was calculated.

    Time frame: Up to 5 years (from Baseline until disease progression or death, whichever occurred first)

  2. Progression-Free Survival (PFS)

    Treatment response was monitored throughout the study and assessed using standardized criteria. Disease progression was defined as the occurrence of at least one of the following: ≥50% increase in the longest diameter of at least two enlarged lymph nodes, increase in spleen and/or liver size by at least 2 cm from Baseline as determined by measurement below the costal margin, or ≥50% increase in the number of circulating lymphocytes. PFS was defined as the time from study inclusion until first event of disease progression or death and was estimated using Kaplan-Meier analysis.

    Time frame: Up to 5 years (from Baseline until disease progression or death, whichever occurred first)

  3. Percentage of Participants Who Died

    Participants were followed for survival throughout the study. The percentage of participants who died of any cause during the study was calculated.

    Time frame: Up to 5 years (from Baseline until death)

  4. Overall Survival (OS)

    Participants were followed for survival throughout the study. OS was defined as the time from study inclusion until death from any cause and was estimated using Kaplan-Meier analysis

    Time frame: Up to 5 years (from Baseline until death)

  5. Percentage of Participants With Complete Response (CR), Nodular Partial Response (nPR), or Partial Response (PR)

    Treatment response was monitored throughout the study and assessed using standardized criteria. CR was defined as hemoglobin ≥11 grams per deciliter (g/dL), lymphocytes less than (\<) 4000 cells per cubic millimeter (cells/mm\^3), neutrophils greater than (\>) 1500 cells/mm\^3, platelets \>100,000 cells/mm\^3, bone marrow (BM) biopsy with \<30% lymphocytes with no lymphocytic infiltrates, no evidence of lymphoid nodules on physical exam, and performance status of 0. PR was defined as \>50% decrease in size of enlarged lymph nodes, hepatomegaly, and splenomegaly, with peripheral counts meeting the same criteria as CR or ≥50% improvement from pre-treatment values. Participants with lymphoid nodules on BM biopsy who otherwise met CR criteria were considered nPR. The percentage of participants with each level of best overall response was calculated.

    Time frame: Up to 4 years (assessed every 3 months during 6-month treatment period, every 2 months during 6-month safety follow-up, then every 3 months during 3-year safety follow-up)

07

Results

Posted May 2, 2016

Participant flow

Participant flow — Overall Study
MilestoneRituximab + Fludarabine + Cyclophosphamide
Started34
Completed23
Not completed11
Withdrew: Adverse event/intercurrent disease3
Withdrew: Death5
Withdrew: Insufficient response/progressed disease1
Withdrew: Lost to follow-up1
Withdrew: Violation of selection criteria1

Outcome measures

PrimaryPercentage of Participants With Death or Disease Progression

Treatment response was monitored throughout the study and assessed using standardized criteria. Disease progression was defined as the occurrence of at least one of the following: greater than or equal to (≥) 50 percent (%) increase in the longest diameter of at least two enlarged lymph nodes, increase in spleen and/or liver size by at least 2 centimeters (cm) from Baseline as determined by measurement below the costal margin, or ≥50% increase in the number of circulating lymphocytes. The percentage of participants with death or documented disease progression at any time during the study was calculated.

Time frame:
Up to 5 years (from Baseline until disease progression or death, whichever occurred first)
Reported as:
Number · percentage of participants
Percentage of Participants With Death or Disease Progression
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Percentage of Participants With Death or Disease Progression24
PrimaryProgression-Free Survival (PFS)

Treatment response was monitored throughout the study and assessed using standardized criteria. Disease progression was defined as the occurrence of at least one of the following: ≥50% increase in the longest diameter of at least two enlarged lymph nodes, increase in spleen and/or liver size by at least 2 cm from Baseline as determined by measurement below the costal margin, or ≥50% increase in the number of circulating lymphocytes. PFS was defined as the time from study inclusion until first event of disease progression or death and was estimated using Kaplan-Meier analysis.

Time frame:
Up to 5 years (from Baseline until disease progression or death, whichever occurred first)
Reported as:
Mean · months
Progression-Free Survival (PFS)
monthsRituximab + Fludarabine + Cyclophosphamide
Progression-Free Survival (PFS)47.2 (42.2 to 52.2)
PrimaryPercentage of Participants Who Died

Participants were followed for survival throughout the study. The percentage of participants who died of any cause during the study was calculated.

Time frame:
Up to 5 years (from Baseline until death)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Percentage of Participants Who Died14
PrimaryOverall Survival (OS)

Participants were followed for survival throughout the study. OS was defined as the time from study inclusion until death from any cause and was estimated using Kaplan-Meier analysis

Time frame:
Up to 5 years (from Baseline until death)
Reported as:
Mean · months
Overall Survival (OS)
monthsRituximab + Fludarabine + Cyclophosphamide
Overall Survival (OS)49.5 (44.8 to 54.2)
PrimaryPercentage of Participants With Complete Response (CR), Nodular Partial Response (nPR), or Partial Response (PR)

Treatment response was monitored throughout the study and assessed using standardized criteria. CR was defined as hemoglobin ≥11 grams per deciliter (g/dL), lymphocytes less than (\<) 4000 cells per cubic millimeter (cells/mm\^3), neutrophils greater than (\>) 1500 cells/mm\^3, platelets \>100,000 cells/mm\^3, bone marrow (BM) biopsy with \<30% lymphocytes with no lymphocytic infiltrates, no evidence of lymphoid nodules on physical exam, and performance status of 0. PR was defined as \>50% decrease in size of enlarged lymph nodes, hepatomegaly, and splenomegaly, with peripheral counts meeting the same criteria as CR or ≥50% improvement from pre-treatment values. Participants with lymphoid nodules on BM biopsy who otherwise met CR criteria were considered nPR. The percentage of participants with each level of best overall response was calculated.

Time frame:
Up to 4 years (assessed every 3 months during 6-month treatment period, every 2 months during 6-month safety follow-up, then every 3 months during 3-year safety follow-up)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR), Nodular Partial Response (nPR), or Partial Response (PR)
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
CR71
nPR9
PR18

Adverse events

Collected over Up to 4 years (assessed every 4 weeks during 6-month treatment period, every 2 months during 6-month safety follow-up, then every 3 months during 3-year safety follow-up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab + Fludarabine + Cyclophosphamide—15/34 (44.1%)18/34 (52.9%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventRituximab + Fludarabine + Cyclophosphamide
Febrile neutropeniaInfections and infestations7/34
NeutropeniaBlood and lymphatic system disorders5/34
FeverGeneral disorders3/34
AnemiaBlood and lymphatic system disorders1/34
Abdominal painGastrointestinal disorders1/34
DeathGeneral disorders1/34
Infusion related reactionGeneral disorders1/34
Bronchial infectionInfections and infestations1/34
SepsisInfections and infestations1/34
Neoplasm (colon)Neoplasms benign, malignant and unspecified (incl cysts and polyps)1/34
Most frequent other events
Most frequent other events
EventRituximab + Fludarabine + Cyclophosphamide
Low plateletsBlood and lymphatic system disorders10/34
AnemiaBlood and lymphatic system disorders8/34
Skin infectionInfections and infestations7/34
LeukopeniaBlood and lymphatic system disorders6/34
HypogammaglobulinemiaBlood and lymphatic system disorders6/34

Baseline characteristics

All Participants Enrolled: All participants who complied with selection criteria at enrollment.

Age, Continuous
Age, Continuous(years)Rituximab + Fludarabine + Cyclophosphamide
Mean60.3 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab + Fludarabine + Cyclophosphamide
Female5
Male29
08

Study locations

9 sites
  • Buenos Aires, 1406, Argentina
  • Buenos Aires, C1114AAN, Argentina
  • Buenos Aires, C1280AEB, Argentina
  • Buenos Aires, C1431FWO, Argentina
  • Córdoba, 5016, Argentina
  • La Plata, B1897GOL, Argentina
  • Pilar, B1629ODT, Argentina
  • Rosario, S2000DSV, Argentina
  • Caracas, 2122, Venezuela
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2015
First posted
Aug 26, 2015
Start
Feb 2006
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
May 2, 2016
Last update
May 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02533401
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 26, 2015
Start date
Feb 2006
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
May 2, 2016
Last update
May 2, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Fludarabine · Rituximab

Start the discussion